CAR-T cell therapy research

This study investigates how the inclusion of the ζ-chain affects phosphotyrosine signaling in CD19-CAR T cells using phosphoproteomics and inhibitor experiments.

This paper introduces a modular CAR-Fab platform that improves cancer immunotherapy by enabling rapid target redirection and reducing antigen loss variant escape.

This paper presents a nanovial-based platform for high-throughput functional screening of CAR T cell libraries, identifying CAR constructs with distinct secretion profiles over time.

This paper develops and validates a dual-targeting CAR-T cell therapy for T-ALL that targets CCR9 and CD1a, showing improved efficacy and safety compared to single-targeting approaches.

Ex vivo profiling of patient CD19 CAR-T cells shows CD28 products skew glycolytic and effector-like while 4-1BB products favor OXPHOS; complete responders show balanced metabolism.

This paper develops WT1-specific CAR T cells that recognize the WT1330-348 peptide across 18 HLA-II alleles, enabling broad therapeutic application.

The paper develops a mechanistic model to predict CAR T cell killing of tumor cells based on contact dynamics and extracts parameters that determine killing efficiency and tumor resilience.

This study develops iPSC-derived T cells targeting the EGFR C797S mutation in NSCLC, showing their ability to recognize and kill cancer cells expressing this mutation.

This paper develops caffeine-responsive switches for CAR T cells, showing they can be controlled by caffeine and effectively clear tumors in mice.

This study engineers CAR Tregs to secrete IL-10 via PDCD1-driven regulation, enhancing their suppressive function in vitro and in vivo.

This study designs and evaluates AI-optimized CAR-T cells with AKT3 degradation to improve persistence and overcome antigen escape in cancer therapy.

This study develops DR5-targeted CAR-T cells that kill solid tumors and MDSCs, enhance CD8+ T cell activity, and show minimal toxicity in preclinical models.

This paper engineers T cells with synthetic receptors that activate only in the lung, demonstrating RAGE as a lung-specific target for targeted therapies.

This paper shows that low-dose radiopharmaceutical therapy enhances GD2 TRAC-CAR T cell efficacy in neuroblastoma by improving tumor regression and immune response.

This paper shows how recombining signaling motifs creates a continuous spectrum of CAR T cell phenotypes, revealing trade-offs between memory, cytotoxicity, and safety.

This study reviews and meta-analyzes CAR-T cell therapy trials and preclinical models to assess their predictive value, finding that preclinical models poorly predict outcomes when using their own features.

This paper reduces TCR mispairing in engineered T cells by disrupting disulfide bonds, improving safety without compromising cytotoxicity.

The paper identifies marker genes associated with cytokine release syndrome (CRS) in CAR T cells before infusion using RNAseq data and clinical outcomes.

This study shows that deleting Regnase-1 in CAR T cells enhances their antitumor activity against osteosarcoma by creating a proinflammatory tumor microenvironment.

This paper develops BCMA CAR T cells with a granzyme B-NOXA fusion to enhance apoptosis in multiple myeloma cells, improving killing efficacy in vitro and in xenograft models.

This study generates CD7 CAR-NK cells from pluripotent stem cells that avoid fratricide and effectively suppress T-cell malignancies in xenograft models.

This paper develops and tests CAR-NK-92 cells targeting Candida albicans mannan, showing enhanced antifungal activity and reduced fungal burden in mice.

This paper evaluates using FAD autofluorescence as a label-free biomarker to monitor T cell activation and expansion in CAR-T cell production.

This paper develops dual-target CAR-γδT cells targeting B7-H3 and IL13Rα2 for glioblastoma therapy, showing superior tumor elimination compared to monospecific CAR-T constructs.

Structure-optimized CD27-based CAR-T cells targeting CD70 show >80-fold improved expansion in vivo and offer a potential therapy for high-risk multiple myeloma patients.

The paper uses Tope-seq to identify cross-reactive epitopes in an engineered T-cell receptor that caused off-target toxicity, highlighting the need for comprehensive screening.

The paper introduces a modular cell line system for rapid in vitro evaluation of CAR-T cells by anchoring ALFA-tagged proteins on the cell surface using anti-ALFA-tag antibodies.

This paper develops a modeling framework to estimate T cell metabolic rates during CAR T cell production and shows correlations between early metabolism and final product attributes.

This paper describes a method to rapidly enrich neoantigen-specific CD8 T cells from peripheral blood, achieving frequencies comparable to tumor-infiltrating lymphocytes over 28 days.

This paper enhances CAR-T cell and TIL anti-tumor activity by epigenetically silencing immune checkpoints and TGFBR2 using Zinc Finger Repressors.